Edition:
India

Athenex Inc (ATNX.OQ)

ATNX.OQ on NASDAQ Stock Exchange Global Select Market

16.83USD
14 Dec 2017
Change (% chg)

$0.03 (+0.18%)
Prev Close
$16.80
Open
$16.80
Day's High
$17.04
Day's Low
$16.79
Volume
92,000
Avg. Vol
62,019
52-wk High
$20.43
52-wk Low
$11.25

Select another date:

Mon, Dec 11 2017

BRIEF-Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis

* ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS

BRIEF-Athenex Announces Planned Retirement Of Chief Financial Officer Nick Riehle

* ATHENEX ANNOUNCES PLANNED RETIREMENT OF CHIEF FINANCIAL OFFICER NICK RIEHLE

BRIEF-Athenex announces Q3 revenue of $14 million

* Says ‍company raises full-year revenue guidance to range of $33 million - $35 million​

BRIEF-Athenex announces positive recommendations from the ‍DSMB to continue the oraxol phase iii program

* Athenex announces positive recommendations from the Drug Safety Monitoring Board to continue the oraxol phase iii program

BRIEF-Athenex Inc announces first patient recruitment in phase III clinical trials for KX-01 ointment

* Athenex, Inc. announces first patient recruitment in phase III clinical trials for KX-01 ointment for actinic keratosis

BRIEF-Athenex Inc announces second quarter 2017 results

* Athenex Inc - ‍expect full-year revenues in range of $30 million to $34 million, inclusive of opportunity created by U.S. sodium bicarbonate shortage​ Source text for Eikon: Further company coverage:

BRIEF-Athenex announces approval of tax incentives from State of New York for Dunkirk facility

* Athenex inc - ‍obtained new york state and local tax incentives related to its pharmaceutical manufacturing facility in town of dunkirk, new york​

BRIEF-Athenex reports commencement of patient enrollment for oraxol-plus-ramucirumab phase 1b clinical trial in gastric cancer

* Athenex Inc. announces commencement of patient enrollment for oraxol-plus-ramucirumab phase 1b clinical trial in gastric cancer Source text for Eikon: Further company coverage:

BRIEF-Huateng Ma reports 11.6 pct passive stake in Athenex

* Huateng Ma reports 11.6 percent passive stake in Athenex Inc as of June 14 - SEC filing Source: (http://bit.ly/2ueJu6F) Further company coverage:

BRIEF-Athenex submits IND application of oraxol to Chinese FDA

* Athenex Inc announces submission of investigational new drug application of oraxol to Chinese FDA

Select another date: